Conventional biomarkers for predicting the efficacy of immunotherapy such as PD-L1 expression, TMB, and MSI usually focus on the expression of tumor cell immunosuppressive molecules and the formation of neoantigens. This evidence concerns the gene CD274 and neoplasm.